Clin2
NCT07392450Possibly a fitRecruiting

Study of TAK-755 for adults with acute ischemic stroke

Acute Ischemic Stroke

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests if TAK-755 can help people who have had a moderate to severe stroke within the last 24 hours. It aims to see if the drug can improve recovery by protecting brain tissue that is still salvageable.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
222 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have had a moderate to severe stroke (NIHSS score 5-25) within 24 hours before starting the study.
  • You must have a blockage in a large artery in the brain, and brain scans must show there is still some healthy brain tissue that could be saved.
  • You must not have had a stroke or major brain injury in the past 90 days.
  • You must not be eligible for or have already received standard clot-busting medicines or clot-removal procedures for this stroke.
  • You must not have any active bleeding or a high risk of bleeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07205328Recruiting· Phase 2
Testing MT200605 for acute ischemic stroke

This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.

Beijing, Beijing Municipality
NCT07371624Recruiting· Phase 1/Phase 2
Study of B2065 for recent ischemic stroke

This trial tests an investigational drug called B2065 for people who have had a recent ischemic stroke (a stroke caused by a blockage in a blood vessel in the brain). The goal is to see if it is safe and if it might help improve recovery when given within 36 hours of stroke symptoms starting.

Beijing
NCT07201688Recruiting· Phase 3
Extending the window for stroke clot-busting drug

This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.

Puyang, Henan
NCT07475949Not yet recruiting· Phase 3
Testing a clot-busting drug for wake-up strokes without advanced scans

This trial tests if the clot-busting drug tenecteplase can help people who have a stroke with an unknown start time (like waking up with symptoms) and cannot get an advanced brain scan. It aims to see if treatment within 3 hours of noticing symptoms is safe and effective.

Nanning, Guangxi
NCT07739160Not yet recruiting· Phase 2
Study of HRS-4029 for acute ischemic stroke

This trial tests a new drug, HRS-4029, given within 3 hours of an ischemic stroke (a stroke caused by a blocked blood vessel). The goal is to see if the drug helps improve recovery.

Beijing, Beijing Municipality
NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.